Today, ILSI, formerly known as the International Life Sciences Institute, announced it has rebranded. The effort includes a new logo, a refreshed visual identity and an updated website, which all reflect the organization’s evolution and its aspirations for the future.
The University of Liverpool’s Digital Innovation Facility (DIF), a £12.7 million Centre of Excellence in emerging digital technologies, has been officially opened by the Liverpool City Mayor, Steve Rotheram. The 1500 M2 facility includes state of the art laboratories featuring cutting edge equipment and highly skilled support to facilitate enhanced access for businesses and organisations that wish to collaborate with University experts across multiple technology areas including virtual reality, robotics, artificial intelligence, data science, simulation and data modelling.
Journal of Integrative and Complementary Medicine (JICM) is honored to announce our new partnership agreement with the Society for Integrative Oncology (SIO).
- Journal of Integrative and Complementary Medicine
NCCN honors oncology leaders Robert Winn, MD, and Shonta Chambers, MSW, named joint Partners in Cancer Care; William Gradishar, MD, named Rodger Winn Award recipient for work on NCCN Guidelines; Hema Sundar, PhD, named Employee of the Year.
Mads Melbye will take up the position as Scientific Director at the Danish Cancer Society on 15 June.
The Journal of Parkinson’s Disease (JPD), published by IOS Press, is pleased to announce the appointment of new co-Editor-in-Chief, Lorraine V. Kalia, MD, PhD, FRCPC. Dr. Kalia joins co-Editor-in-Chief Bas Bloem, MD, PhD, FRCPE, and an eminent international editorial board, who are dedicated to the continuing success of the world’s leading journal in Parkinson’s research.
The NASA Lucy mission, led by Principal Investigator Dr. Hal Levison of Southwest Research Institute, successfully observed the May 2022 total lunar eclipse from a unique vantage point 64 million miles (100 million km) from the Earth.
In partnership with Verizon, the NYC Media Lab at the NYU Tandon School of Engineering today announced the winners of the $1M Museum Initiative—a nationwide open call for museums and cultural institutions to develop and offer new immersive educational content available to all educators on the Verizon Innovative Learning HQ portal.
Northpond Labs, the R&D-focused affiliate of Northpond Ventures, has signed an agreement to support a second Wyss Institute project and accelerate its development toward commercialization. The new agreement funds SomaCode, led by Soufiane Aboulhouda, Oliver Dodd, and George Church, Ph.D. SomaCode aims to solve a key problem plaguing cell therapies: delivering therapeutic cells to their targets in the body. Because cell therapies are administered via the blood, it's currently very difficult to get them to home to a specific organ or tissue. SomaCode’s pooled in vivo discovery platform identifies molecular "zip codes" on target tissues that can be used to improve immune cell delivery to solid tumors and other diseases.
In the framework of an EXIST Transfer of Research project, the HETEROMERGE team is developing a technology for automated material exchange for high-precision 3D printers toward market maturity, enabling multi-material printing even in the area of extremely small structure sizes of down to 100 nanometers. With this innovation, the team currently is competing for this year's Founders Award of Saxony's innovation hub ‘futureSAX’. HETEROMERGE can still be voted for in the futureSAX Audience Award until 31.05.2022.
The research and resource development efforts of the Rett Syndrome Research Trust (RSRT) have helped generate an eighth biopharmaceutical program that tackles the root cause of Rett syndrome. Neurogene, a company founded on the vision to push the boundaries of genetic medicine to address complex and devastating neurological diseases, today announced that it will be expanding the company’s development pipeline with the addition of NGN-401 for Rett syndrome. NGN-401 is a gene replacement approach that utilizes Neurogene’s novel EXACT gene regulation technology. Stuart Cobb, PhD, Chief Scientific Officer at Neurogene and Simons Fellow at the University of Edinburgh, presented preclinical efficacy and safety data for NGN-401 at the 25th Annual Meeting of the American Society for Gene and Cell Therapy. Gene replacement is one of six strategies championed by RSRT to target the root cause of Rett syndrome and is the strategy closest to the clinic.